Sharemaestro Newsreel

Steris Posts Solid Q1 Results Amid Restructuring Plans

STERIS (STE) reported strong fiscal 2027 first-quarter results with 7% revenue growth and increased EPS, driven by its Healthcare segment and solid gains in Life Sciences and Applied Sterilization Technologies. The company announced a restructuring plan involving facility consolidations, incurring estimated charges of $55-70 …

Needham raises Establishment Labs stock price target on strong results

Hyperfine (HYPR) Releases Q2 2026 Earnings: Revenue Growth but EPS in Line

Haemonetics Corporation 2027 Q1 - Results - Earnings Call Presentation (NYSE:HAE) 2026-08-06

Sanuwave Announces Q2 FY2026 Financial Results

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025. EDEN PRAIRIE, Minn., …

Beyond Air regains Nasdaq bid-price compliance after 1-for-20 reverse split; discretionary monitor imposed

Beyond Air (XAIR) has regained compliance with Nasdaq's $1.00 bid-price rule following a 1-for-20 reverse stock split effected on July 13, 2026. The company maintained a closing bid price of $1.00 or greater for 17 consecutive trading days. Nasdaq has imposed a one-year Discretionary …

Form 8K Beyond Air Inc For: 6 August By Investing.com

This article from Investing.com reports on Beyond Air Inc.'s Form 8K filing for August 6th. The content primarily consists of market data, including various indices, commodities, currencies, and stock performance, but offers no further details on the specific contents of Beyond Air's filing. It …

Hyperfine Q2 2026 earnings: Revenue rises 45% as operating loss narrows

Hyperfine (Nasdaq: HYPR) reported a 44.8% increase in Q2 2026 revenue, reaching $3.904 million, with commercial Swoop system sales rising and gross margin expanding, which helped narrow the operating loss. Despite operational improvements, the net loss remained nearly flat at $9.298 million due to …

Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers

Artivion (NYSE:AORT) reported strong Q2 CY2026 results, with revenue of $125.8 million, beating analyst estimates by 4.4%, and non-GAAP EPS of $0.13, exceeding estimates by 34.5%. The medical device company reconfirmed its full-year revenue guidance and provided optimistic EBITDA guidance. Despite a decrease in …

electroCore Announces Second Quarter 2026 Financial Results

electroCore announced strong second-quarter 2026 financial results, with net sales increasing by 28% to $9.5 million, driven by growth in U.S. prescription sales and Truvaga sales. The company reduced its net loss by 17% and improved Adjusted EBITDA by 26% year-over-year. electroCore also raised …

[10-Q] electroCore, Inc. Quarterly Earnings Report

electroCore, Inc. (ECOR) filed its quarterly earnings report (Form 10-Q) for the period ending June 30, 2026, revealing funding shortfalls and raising substantial doubt about its ability to continue as a going concern. The company reported a net loss of $8.3 million for the …

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported a second-quarter loss of $13.5 million, or 28 cents per share, which contrasts with a profit in the same period last year. Adjusted earnings for the biological medical device maker were 13 cents per share, with revenue reaching $130.8 million. …

Earnings Flash (AORT) Artivion, Inc. Reports Q2 Revenue $125.8M, vs. FactSet Est of $120.0M

Artivion, Inc. (AORT) has reported its Q2 revenue of $125.8 million, surpassing FactSet's estimate of $120.0 million. This earnings flash indicates a positive financial performance for the medical device company. The news was published on August 6, 2026, at 05:07 pm EDT.

Outset Medical Inc. (OM) Misses Q2 EPS by 5c

Outset Medical Inc. (OM) reported its Q2 earnings, missing analyst estimates for EPS by $0.05, with an EPS of ($0.80) against an anticipated ($0.75). Despite the EPS miss, the company slightly exceeded revenue expectations, bringing in $31.6 million compared to the consensus estimate of …

Globus Medical lifts 2026 non-GAAP EPS guidance to $4.95-$5.05

Globus Medical Reports Second Quarter 2026 Results

Globus Medical AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: Worldwide net sales were $789.6 million, an increase …

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Senseonics Holdings, Inc. announced strong second-quarter 2026 financial results, with revenue growing approximately 120% year-over-year to $14.5 million and gross margin reaching 59%. The company raised its full-year 2026 revenue guidance to $62 million to $66 million and gross margin guidance to 58% to …

Hyperfine, Inc. (NASDAQ: HYPR) grows Q2 sales but remains unprofitable

electroCore (NASDAQ: ECOR) lifts 2026 outlook after 28% Q2 growth

Sight Sciences Inc (SGHT) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and Raised ...

Sight Sciences Inc. (SGHT) reported strong Q2 2026 earnings, featuring a 20% year-over-year increase in total revenue to $23.4 million, marking its strongest quarterly growth in three years. The company also saw significant improvement in its interventional dry eye revenue, which nearly doubled, and …

AVITA Medical Q2 revenue rises 18% to $21.7M; raises 2026 guidance, expects Q4 cash-flow breakeven

AVITA Medical reported strong Q2 2026 financial results with revenue increasing 18% year-over-year to $21.7 million, driven by the success of RECELL, Cohealyx, and PermeaDerm. The company narrowed its net loss and raised its full-year 2026 revenue guidance to $86-$89 million, projecting cash-flow breakeven …

iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm Holdings, Inc. announced its definitive agreement to acquire VitalConnect for approximately $287.5 million, comprising cash and iRhythm common stock. This acquisition is expected to broaden iRhythm's cardiac monitoring platform by adding mobile cardiac telemetry and multi-vitals monitoring capabilities, expanding its addressable market across …

Accuray Announced Transfer or Voluntary Withdrawal of Listing

Accuray (ARAY) has received Nasdaq approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective August 6, 2026. The company retains its ARAY symbol and has an additional 180 days, until February 1, 2027, to …

908 Devices Inc. (MASS) holder AWM sells 50,000 shares, keeps 4.83M

AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc. (MASS), indirectly sold 50,000 shares of Common Stock on August 4, 2026, at a weighted average price of $8.3553 per share. Following this transaction, AWM's aggregate holdings through advised limited partnerships amount …

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Apyx Medical Corporation reported its second-quarter 2026 financial results, with total revenue of $13.9 million, primarily driven by a 28% growth in its Surgical Aesthetics segment. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and highlighted the successful …

Apyx Medical Reports Q2 2026 Revenue of $13.9M, Surgical Aesthetics Up 28%

Apyx Medical announced its Q2 2026 financial results, reporting total revenue of $13.9 million, a 22% year-over-year increase, largely driven by a 28% growth in its Surgical Aesthetics segment. Despite a GAAP net loss of $3.2 million and an adjusted EBITDA loss of $0.7 …

Apyx Medical’s AYON System Gains FDA 510(k) Clearance for Power Liposuction

Apyx Medical reported Q2 2026 revenue of $13.9 million, a 22% year-over-year increase, primarily driven by 28% growth in its Surgical Aesthetics segment. The company also announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction and reaffirmed its …

Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX

Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with …

Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research

BTIG Research has raised its price target for Delcath Systems (NASDAQ:DCTH) to $21.00 from $17.00, maintaining a "Buy" rating and implying a 40% upside. This follows Delcath's strong quarterly performance, where it exceeded revenue and EPS expectations. The stock surged 18.8% to $15.00 on …

Profound Medical (NASDAQ: PROF) boosts revenue 62% while cutting loss

Profound Medical Corp. (NASDAQ: PROF) announced a significant revenue increase of 62% for the six months ended June 30, 2026, reaching $7.82 million, primarily due to higher capital equipment sales and recurring non-capital revenue. The company also narrowed its net loss to $16.59 million …

About $3.1M of Profound shipments will count as Q3 revenue

Profound Medical (NASDAQ:PROF) reported Q2 2026 revenue of $2.5 million, an increase of 12% year-over-year. Approximately $3.1 million in TULSA shipments were delayed to July due to logistics, which would have increased Q2 revenue to $5.6 million, representing 153% growth. The company reiterated its …

CVRx (NASDAQ: CVRX) grows Q2 2026 revenue but cuts outlook

CVRx, Inc. reported a 16% increase in Q2 2026 revenue to $15.7 million, primarily driven by U.S. heart failure sales, with gross profit rising to $13.7 million and gross margin improving to 87%. Despite this growth, the company posted a net loss of $14.0 …

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRx, Inc. announced its Q2 2026 financial results, reporting $15.7 million in total revenue, a 16% increase year-over-year, and a gross margin of 87%. Despite strong growth and a new Medicare Advantage coverage policy from Humana for its Barostim therapy, the company updated its …

Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11

This article announces that NeuroPace is scheduled to release its financial results after the market closes on August 11. Investors and analysts will be keen to review the company's performance and outlook during the upcoming earnings call.

Earnings call transcript: Enovis tops Q2 2026 EPS view but shares fall 6.7%

iRhythm Holdings Announces Second Quarter 2026 Financial Results

iRhythm SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2026. Second …